Federal contract award
75N93020C00040
ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $10.7M |
| Current contract value | $10.7M |
| Potential contract value / ceiling | $26.4M |
| Start date | Jul 21, 2020 |
| Current end date | Dec 31, 2026 |
| Potential end date | Dec 31, 2026 |
| Latest award activity | Sep 8, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 20 of 20 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 8, 2026 | P00019 | $-22.1K | TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Jun 4, 2026 | P00018 | $0 | ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Dec 1, 2025 | P00017 | $0 | ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Sep 30, 2025 | P00016 | $6.8K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Apr 4, 2025 | P00015 | $0 | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Nov 6, 2024 | P00014 | $55.1K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Sep 23, 2024 | P00013 | $-16.9K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Aug 1, 2024 | P00012 | $0 | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| May 15, 2024 | P00011 | $-33.8K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| May 1, 2024 | P00010 | $700.8K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Mar 6, 2024 | P00009 | $0 | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Aug 31, 2023 | P00008 | $1.7M | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Jun 12, 2023 | P00007 | $2.3M | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Mar 14, 2023 | P00006 | $0 | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Sep 22, 2022 | P00005 | $-14.6K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Jun 29, 2022 | P00004 | $-6.4K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Apr 1, 2022 | P00003 | $100.0K | EO 14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Nov 2, 2021 | P00002 | $0 | EO14042 ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Mar 24, 2021 | P00001 | $986.6K | ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
| Jul 21, 2020 | 0 | $4.9M | ADVANCED DEVELOPMENT OF MULTIVALENT VACCINE CANDIDATES FOR FILOVIRUS AND LASSA FEVER |
Estimated positioning window
Oct 25, 2026 – Jan 23, 2027
Recompete signal: . Rule-based research score; positioning dates are estimates.
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2026-12-31 (67 days from calculation)
- +35 points
- 103 historical awards in this buyer and category group
- +15 points
- 20 recorded award transactions
- +10 points
- Latest award action: 2026-09-08
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.